Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

APOE and dementia - resequencing and genotyping in 105,597 individuals

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Replication study of plasma proteins relating to Alzheimer's pathology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Shift work and incidence of dementia: A Danish Nurse Cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Declining incidence of dementia: A national registry-based study over 20 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. HIV infection is associated with type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: The mechanism behind the strong association between the ɛ2/ɛ3/ɛ4 apolipoprotein E gene (APOE) polymorphism and Alzheimer's disease is not well-characterized. Because low plasma levels of apoE associate with risk of dementia, genetic variants altering apoE levels in general may also associate with dementia.

METHODS: The APOE gene was sequenced in 10,369 individuals, and nine amino acid-changing variants with frequencies ≥2/10,000 were further genotyped in 95,228 individuals. Plasma apoE levels were measured directly.

RESULTS: Risk of all dementia and Alzheimer's disease (AD) increased with decreasing genetically determined apoE levels (P = 5 × 10-4 and P = 1 × 10-4 after APOE ɛ2/ɛ3/ɛ4 adjustment). Hazard ratios (95% confidence intervals) for all dementia and AD were 2.76 (1.39 to 5.47) and 4.92 (2.36 to 10.29) for the group with the genetically lowest apoE versus ɛ33.

DISCUSSION: We found that genetically low apoE levels increase and genetically high levels decrease risk, beyond ɛ2/ɛ3/ɛ4. This underscores that dementia risk more likely relates to variants affecting levels of apoE.

OriginalsprogEngelsk
TidsskriftAlzheimer's & dementia : the journal of the Alzheimer's Association
Vol/bind16
Udgave nummer12
Sider (fra-til)1624-1637
Antal sider14
ISSN1552-5260
DOI
StatusUdgivet - dec. 2020

Bibliografisk note

© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.

ID: 61972804